ERBB3 and neoplasm: Zenocutuzumab (MCLA-128) is a HER2/HER3-targeting BSAB that functions by docking and blocking the structural domains of these proteins, thereby preventing the binding of NRG1-HER3 ligands and NRG1 fusion proteins and subsequently disrupting the downstream signaling pathways to produce an anti-tumor effect.